12-03-2018
Our new website has been launched with the aim of being the corporate showcase for the Group formed from the union of the Spanish companies Inke, Laboratories Lesvi and Qualigen, the German company neuraxpharm and the Italian company FB Health.
The website highlights all the information concerning the Group’s CNS drugs: branded medicines, generic medicines and nutraceutical medicines. The website also shows the size and potential of the Group, its commitment to R&D, its sales force and production capabilities.
Along with the website, the Group has also introduced a corporate image and logo—in the shape of a neurone—that demonstrate its focus on CNS disorders.
Another important element of the Group’s visual identity is the image of a lighthouse, symbolising NuPharm’s aim to be a leading light in the treatment these disorders, whilst also referring to the fact that patients must be able to rely on the best alternatives to deal with their disorders.
www.nupharm.com
During 2023, Inke has increased its production capacity by making a significant investment in new reactors and clean rooms. This initiative has been carried out with the support of ACCIÓ from the Generalitat de Catalunya.
Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity.
